Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.54 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.46 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.46 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.44 |
| ▸ | RAMP3 | O60896 | 6/20 | 0.43 |
| ▸ | CALCR | P30988 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170451 | 0.97 | APLNR (0.53) | APLNRNMUR2NMUR1NAA50OPRD1 | |
| SCHEMBL30933156 | 0.97 | APLNR (0.53) | APLNRNMUR2NMUR1NAA50OPRD1 | |
| SCHEMBL30933143 | 0.97 | APLNR (0.53) | APLNRNMUR2NMUR1NAA50OPRD1 | |
| SCHEMBL30933096 | 0.96 | APLNR (0.51) | APLNRNMUR2NMUR1NAA50OPRD1 | |
| SCHEMBL30933095 | 0.96 | APLNR (0.54) | APLNRNMUR2NMUR1NAA50OPRD1 | |
| SCHEMBL30918801 | 0.96 | APLNR (0.52) | APLNRNMUR2NMUR1NAA50OPRD1 | |
| SCHEMBL30933116 | 0.95 | APLNR (0.51) | APLNRNAA50OPRD1RENRAMP3 | |
| SCHEMBL30933079 | 0.95 | APLNR (0.51) | APLNRNMUR2NMUR1NAA50RAMP3 | |
| SCHEMBL30933099 | 0.95 | APLNR (0.51) | APLNRNMUR2NMUR1NAA50OPRD1 | |
| SCHEMBL30933097 | 0.94 | APLNR (0.51) | APLNRNAA50OPRD1RENRAMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113474356-B | Peptides and pharmaceutical compositions for the treatment of ocular diseases | 株式会社柳柳制药 | 2024-12-17 | — | — | CN | disclosed |